$CTIC News
Last published 1y ago
- 1y agoCTICCTI BioPharma Corp. - Appeal, ReversedUS Patent Trial and Appeal Board
- 1y agoCTICCTI BioPharma Corp. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 3y agoCTICSEC Charges Former Attorney at U.S.-Based Global Law Firm with Insider TradingSEC Press ReleasesThe Securities and Exchange Commission today announced insider trading charges against Romero Cabral da Costa Neto for trading based on material, nonpublic information concerning a client of the global law firm where he worked as a visiting attorney from…
- 3y agoCTICSobi completes acquisition of CTI BioPharma Corp.PR NewswireSTOCKHOLM, June 26, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) announced today the completion of the acquisition of CTI by Sobi through its
- 3y agoCTICSobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.PR NewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS
- 3y agoCTICCTI BioPharma Announces Cancellation of its 2023 Annual Meeting of StockholdersPR NewswireSEATTLE, May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for
- 3y agoABSTCTICFRGHMPTMoore Kuehn Encourages HMPT, ABST, CTIC and FRG Investors to Contact Law FirmPR NewswireNEW YORK, May 16, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoCTICSobi to Acquire CTI BioPharmaPR NewswireTransaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE, May 10, 2023 /PRNewswire/ -- CTI BioPharma (NASDAQ:CTIC) ("CTI"), a commercial
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, May 4, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, May 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today
- 3y agoCTICCTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingPR Newswire– Data presentation on spleen volume reduction in patients with myelofibrosis also accepted for poster discussion – SEATTLE, May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical
- 3y agoCTICCTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023PR NewswireSEATTLE, Wash., April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, April 10, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers,
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, March 20, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers,
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, March 6, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers,
- 3y agoCTICCTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial ResultsPR Newswire– Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1
- 3y agoCTICCTI BioPharma to Present at the 43rd Annual Cowen Health Care ConferencePR NewswireSEATTLE, March 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers,
- 3y agoCTICCTI BioPharma To Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Monday, March 6, 2023PR NewswireSEATTLE, Feb. 23, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers,
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, Feb. 7, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees
- 3y agoCTICCTI BioPharma to Participate in Upcoming Investor Conferences in February 2023PR NewswireSEATTLE, Feb. 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023: Guggenheim
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, Jan. 24, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee
- 3y agoCTICCTI BioPharma to Present at the 41st Annual J.P. Morgan Healthcare ConferencePR NewswireSEATTLE, Jan. 5, 2023 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference in San
- 3y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, Dec. 20, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new
- 3y agoCTICCTI BioPharma Presents New Anemia Benefit Data from Pacritinib Program at the 2022 American Society of Hematology (ASH) Annual Meeting and ExpositionPR NewswireSEATTLE, Dec. 11, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of
- 3y agoBVAXFCTICIMGNMRK+1Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling HopePR NewswireFinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The global ovarian cancer market is projected to continue to grow through the coming several years. The formation of mutational cells
- 3y agoCTICCTI BioPharma to Present at the JMP Securities Hematology and Oncology SummitPR NewswireSEATTLE, Nov. 30, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET. The
- 4y agoCTICCTI BioPharma to Present at Upcoming November ConferencesPR NewswireSEATTLE, Nov. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York and London. Presentation
- 4y agoCTICCTI BioPharma Reports Third Quarter 2022 Financial ResultsPR Newswire– VONJO® (pacritinib) net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter – – Increase in sales reflects strong growth in new patient starts – – Oral presentation
- 4y agoCTICCTI BioPharma Announces Oral Presentation at the 2022 American Society of Hematology (ASH) Annual Meeting and ExpositionPR NewswireSEATTLE, Nov. 3, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced an oral presentation and two poster presentations from the Company's pacritinib program at the 64th American Society of
- 4y agoCTICCTI BioPharma to Report Third Quarter 2022 Financial Results on November 7, 2022PR NewswireSEATTLE, Oct. 27, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its third quarter 2022 financial results on Monday, November 7, 2022, after the
- 4y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, Oct. 17, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees
- 4y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced the grant of equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the
- 4y agoCTICCTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic Oncology (SOHO) Tenth Annual MeetingPR NewswireSEATTLE, Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced two poster presentations from the Company's pacritinib program at the Society of Hematologic Oncology (SOHO) Tenth Annual Meeting, to be held in Houston, Texas and
- 4y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, Aug. 22, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outsid
- 4y agoCTICCTI BioPharma Reports Second Quarter 2022 Financial ResultsPR Newswire– VONJO® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET – SEATTLE, Aug. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financ
- 4y agoCTICCTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022PR Newswire– Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit – SEATTLE, Aug. 1, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to rep
- 4y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, June 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outsi
- 4y agoCTICCTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 CongressPR NewswireSEATTLE, June 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced two scientific poster presentations from the Company's pacritinib clinical program at the European Hematology Association (EHA) 2022 Congress, being held in Vienna,
- 4y agoCALTCELUCTICKURA+1Celularity Appoints Industry Leader Diane Parks to its Board of DirectorsGlobeNewswireFLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Pa
- 4y agoCTICCTI BioPharma to Present at Upcoming June ConferencesPR NewswireSEATTLE, June 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York City. Presentation details: Event: Jefferies Healthcare Confere
- 4y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, May 27, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outsi
- 4y agoCTICCTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual MeetingPR NewswireSEATTLE, May 26, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced a poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtual
- 4y agoCTICCTI BioPharma Reports First Quarter 2022 Financial ResultsPR Newswire– Strong U.S. commercial launch of VONJO™ (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia – – VONJO (pacritinib) net product revenue of $2.3 million in less t
- 4y agoCTICCTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual MeetingPR NewswireSEATTLE, May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtu
- 4y agoCTICCTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR NewswireSEATTLE, May 5, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and R
- 4y agoCTICCTI BioPharma to Report First Quarter 2022 Financial Results on May 12, 2022PR NewswireSEATTLE, April 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ:CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets.
- 4y agoBVAXFCLVSCTICIMGN+1Advanced Immunological and Clinical Trials for Treating Ovarian Cancer AcceleratingPR NewswirePALM BEACH, Fla., April 25, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer remains undetected until the mutation spre
- 4y agoCTICNCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative NeoplasmsPR NewswireVONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count SEATTLE, April 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that VONJO™ (pacritinib), its novel oral
- 4y agoAALATRSCLSNCTIC+1Thinking about buying stock in Antares Pharma, Celsion Corp, American Airlines, Kaleido Biosciences, or CTI BioPharma?PR NewswireNEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRS, CLSN, AAL, KLDO, and CTIC.
- 4y agoCTICCTI BioPharma to Present at the 21st Annual Needham Virtual Healthcare ConferencePR NewswireSEATTLE, April 6, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference at 1:30 p.m. ET. The conference will be held in a virtua